Potencies and unblocking kinetic properties of antagonists at recombinant human NMDA receptors in a Xenopus oocytes model

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 388, Issue 5, 2015, Pages 509-516

  Heusler, Peter ^a   Tourette, Amélie ^a   Cussac, Didier ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Current unblocking kinetics; Human recombinant NMDA receptor; Ketamine; Memantine; NR2B NMDA receptor subunit; Xenopus oocytes

Indexed keywords

DULOXETINE; GLUTAMIC ACID; GLYCINE; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; TRAXOPRODIL; AMINO ACID RECEPTOR BLOCKING AGENT; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NR2B NMDA RECEPTOR; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; ELECTROPHYSIOLOGICAL PROCEDURES; GENE EXPRESSION SYSTEM; HUMAN; IN VITRO STUDY; NONHUMAN; OOCYTE; RECEPTOR BLOCKING; STEADY STATE; XENOPUS; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; GENETICS; KINETICS; MEMBRANE POTENTIAL; METABOLISM; PATCH CLAMP TECHNIQUE; XENOPUS LAEVIS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KINETICS; MEMANTINE; MEMBRANE POTENTIALS; OOCYTES; PATCH-CLAMP TECHNIQUES; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; XENOPUS LAEVIS;

EID: 84939417404     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-015-1085-6     Document Type: Article

References (30)

1. Balu DT, Coyle JT (2014) The NMDA receptor 'glycine modulatory site' in schizophrenia: d-serine, glycine, and beyond. Curr Opin Pharmacol 20C:109-115, PM:25540902
2. Calabrese F, Guidotti G, Molteni R, Racagni G, Mancini M, Riva MA (2012) Stress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment. PLoS One 7:e37916, PM:22666412
3. de Bartolomeis A, Sarappa C, Magara S, Iasevoli F (2012) Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. Eur J Pharmacol 682:1-11, PM:22387855
4. Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacol Rev 51:7-61, PM:10049997
5. Donevan SD, McCabe RT (2000) Conantokin G is an NR2B-selective competitive antagonist of N-methyl-d-aspartate receptors. Mol Pharmacol 58:614-623, PM:10953056
6. Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, Almonte A, Murray E, Mosely C, Barber J, French A, Balster R, Murray TF, Traynelis SF (2007) Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol 581:107-128, PM:17303642
7. Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT (2004) Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol 141:508-516, PM:14718249
8. Feuerbach D, Loetscher E, Neurdin S, Koller M (2010) Comparative pharmacology of the human NMDA-receptor subtypes R1-2A, R1-2B, R1-2C and R1-2D using an inducible expression system. Eur J Pharmacol 637:46-54, PM:20394742
9. Ghasemi M, Phillips C, Trillo L, De Miguel Z, Das D, Salehi A (2014) The role of NMDA receptors in the pathophysiology and treatment of mood disorders. Neurosci Biobehav Rev 47C:336-358, PM:25218759
10. Gilling KE, Jatzke C, Hechenberger M, Parsons CG (2009) Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-d-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. Neuropharmacology 56:866-875, PM:19371579
11. Hedegaard M, Hansen KB, Andersen KT, Brauner-Osborne H, Traynelis SF (2011) Molecular pharmacology of human NMDA receptors. Neurochem Int. PM:22197913
12. Hess SD, Daggett LP, Crona J, Deal C, Lu CC, Urrutia A, Chavez-Noriega L, Ellis SB, Johnson EC, Velicelebi G (1996) Cloning and functional characterization of human heteromeric N-methyl-d-aspartate receptors. J Pharmacol Exp Ther 278:808-816, PM:8768735
13. Heusler P, Pauwels PJ, Wurch T, Newman-Tancredi A, Tytgat J, Colpaert FC, Cussac D (2005) Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling. Neuropharmacology 49:963-976, PM:15964603
14. Johnson JW, Kotermanski SE (2006) Mechanism of action of memantine. Curr Opin Pharmacol 6:61-67, PM:16368266
15. Lai TW, Shyu WC, Wang YT (2011) Stroke intervention pathways: NMDA receptors and beyond. Trends Mol Med 17:266-275, PM:21310659
16. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160-170, PM:16424917
17. Mony L, Kew JN, Gunthorpe MJ, Paoletti P (2009) Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 157:1301-1317, PM:19594762
18. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, Traynelis SF, Dingledine R (1998) Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1:659-667, PM:10196581
19. Nagata T, Ueno S, Morita H, Kubota T, Toyohira Y, Tsutsui M, Tawara A, Yanagihara N (2008) Direct inhibition of N-methyl-d-aspartate (NMDA)-receptor function by antiglaucomatous beta-antagonists. J Pharmacol Sci 106:423-434, PM:18319565
20. Paoletti P, Neyton J (2007) NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 7:39-47, PM:17088105
21. Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383-400, PM:23686171
22. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239-1258, PM:8570022
23. Petrenko AB, Yamakura T, Sakimura K, Baba H (2014) Defining the role of NMDA receptors in anesthesia: are we there yet? Eur J Pharmacol 723:29-37, PM:24333550
24. Planells-Cases R, Montoliu C, Humet M, Fernandez AM, Garcia-Martinez C, Valera E, Merino JM, Perez-Paya E, Messeguer A, Felipo V, Ferrer-Montiel A (2002) A novel N-methyl-d-aspartate receptor open channel blocker with in vivo neuroprotectant activity. J Pharmacol Exp Ther 302:163-173, PM:12065713
25. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631-637, PM:19011431
26. Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62:63-77, PM:21827775
27. Tarawneh R, Galvin JE (2010) Potential future neuroprotective therapies for neurodegenerative disorders and stroke. Clin Geriatr Med 26:125-147, PM:20176298
28. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405-496, PM:20716669
29. Wang SY, Calderon J, Kuo WG (2010) Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology 113:655-665, PM:20693878
30. Williams K (1993) Ifenprodil discriminates subtypes of the N-methyl-d-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44:851-859, PM:7901753